🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Matthew J. Wakefield

The University of Melbourne

ORCID: 0000-0001-6624-4698

Also affiliated with Walter and Eliza Hall Institute of Medical Research

MedicineBiochemistry, Genetics and Molecular BiologyAgricultural and Biological Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile
2.7Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

MaveDB 2024: a curated community database with over seven million variant effects from multiplexed functional assays

Genome biology(2025)10.1186/s13059-025-03476-y
Top 12%
1.7DataRank
Top 12%70 citations

Jeremy Stone, Aisha Haley Bianchi, Benjamin J. Capodanno, Estelle Y. Da, Mafalda Dias +23 more

Papers

Driven by 14 papers — median percentile 83. Top paper: “MaveDB 2024: a curated community database with over seven million variant effects from multiplexed functional assays”.

MaveDB 2024: a curated community database with over seven million variant effects from multiplexed functional assays

Genome biology(2025)10.1186/s13059-025-03476-y
Top 12%
1.7DataRank
Top 12%70 citations

Jeremy Stone, Aisha Haley Bianchi, Benjamin J. Capodanno, Estelle Y. Da, Mafalda Dias +23 more

Erratum: Genome analysis of the platypus reveals unique signatures of evolution

Nature(2008)10.1038/nature07253
N/A
1.6DataRank · unranked
35 citations

LaDeana W. Hillier, Jennifer A. Marshall Graves, Kerstin Lindblad‐Toh, Elaine A. Ostrander, Frank Grützner +115 more

MaveDB v2: a curated community database with over three million variant effects from multiplexed functional assays

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.11.29.470445
Top 21%
0.975DataRank
Top 21%28 citations

Joseph Min, Nathan Rollins, Estelle Y. Da, Daniel Esposito, Matthew Harrington +19 more

Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.12.10.419176
N/A
0DataRank · unranked
2 citations

Olga Kondrashova, Rachel M. Hurley, Cordelia D. McGehee, Cassandra J. Vandenberg, Gwo‐Yaw Ho +26 more

Characterization of a RAD51C -Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.12.25.419978
N/A
0DataRank · unranked
2 citations

Cordelia D. McGehee, Ksenija Nesic, Cristina Correia, Taylor M. Weiskittel, Rebecca L. Kelly +25 more

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma

Cancer Research(2021)10.1158/0008-5472.can-21-0774
N/A
0DataRank · unranked
89 citations

Olga Kondrashova, Rachel M. Hurley, Cordelia D. McGehee, Cassandra J. Vandenberg, Gwo‐Yaw Ho +25 more

Characterization of a RAD51C -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance

NAR Cancer(2021)10.1093/narcan/zcab028
N/A
0DataRank · unranked
37 citations

Cordelia D. McGehee, Ksenija Nesic, Cristina Correia, Taylor M. Weiskittel, Rebecca L. Kelly +28 more

Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1206
N/A
0DataRank · unranked
21 citations

Kylie L. Gorringe, Matthew J. Wakefield, Adelyn Bolithon, Chi Nam Ignatius Pang, Derek S. Chiu +95 more

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance

medRxiv(2023)10.1101/2023.03.20.23287465
N/A
0DataRank · unranked
9 citations

John J. Krais, Cassandra J. Vandenberg, Yifan Wang, Pooja Patel, Kathy Q. Cai +30 more

Data from Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma

(2023)10.1158/0008-5472.c.6513498.v1
N/A
0DataRank · unranked
0 citations

Olga Kondrashova, Rachel M. Hurley, Cordelia D. McGehee, Cassandra J. Vandenberg, Gwo‐Yaw Ho +25 more

The role of aberrant DNA methylation in cancer initiation and clinical impacts

Therapeutic Advances in Medical Oncology(2024)10.1177/17588359231220511
N/A
0DataRank · unranked
94 citations

Ksenija Nesic, Olga Kondrashova, Alexander Dobrovic, Elizabeth M. Swisher, Clare L. Scott +2 more

CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer

iScience(2024)10.1016/j.isci.2024.109978
N/A
0DataRank · unranked
12 citations

Sarah B. Gitto, Gwo‐Yaw Ho, Sergey Medvedev, Kristy Shield‐Artin, Hyoung Kim +15 more

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Modern Pathology(2020)10.1038/s41379-020-0618-9
N/A
0DataRank · unranked
43 citations

Dane Cheasley, Cécile Le Page, Matthew J. Wakefield, Michelle da Cunha Torres, Simone M. Rowley +93 more

Therapeutic options for mucinous ovarian carcinoma

Gynecologic Oncology(2020)10.1016/j.ygyno.2019.12.015
N/A
0DataRank · unranked
95 citations

Dane Cheasley, Matthew J. Wakefield, Georgina L. Ryland, Prue E. Allan, Kathryn Alsop +35 more